Drug Profile
Research programme: obesity therapy - Myriad Pharmaceuticals
Alternative Names: MPI 176792; MPI 6802; obesity therapy research programme - Myriad PharmaceuticalsLatest Information Update: 13 Aug 2007
Price :
$50
*
At a glance
- Originator Myriad Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 13 Aug 2007 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 19 Apr 2006 No development reported - Preclinical for Obesity in USA (unspecified route)
- 03 Oct 2005 Myriad announced the discovery of COB1, the first common gene to be associated with childhood obesity